Cited by 420Cancer Cells and MetastasisBreast Cancer Treatment Studies3D Printing in Biomedical Research

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Open access

Guillen, Katrin P., Fujita, Maihi, Butterfield, Andrew J., Scherer, Sandra D., Bailey, Matthew H., Chu, Zhengtao, DeRose, Yoko S., Zhao, Ling, Cortes-Sanchez, Emilio, Yang, Chieh-Hsiang, Toner, Jennifer, Wang, Guoying, Qiao, Yi, Huang, Xiaomeng, Greenland, Jeffery A., Vahrenkamp, Jeffery M., Lum, David H., Factor, Rachel E., Nelson, Edward W., Matsen, Cindy B., Poretta, Jane M., Rosenthal, Regina, Beck, Anna C., Buys, Saundra S., Vaklavas, Christos, Ward, John H., Jensen, Randy L., Jones, Kevin B., Li, Zheqi, Oesterreich, Steffi, Dobrolecki, Lacey E., Pathi, Satya S., Woo, Xing Yi, Berrett, Kristofer C., Wadsworth, Mark E., Chuang, Jeffrey H., Lewis, Michael T., Marth, Gabor T., Gertz, Jason, Varley, Katherine E., Welm, Bryan E., Welm, Alana L.·2022·Nature Cancer

DOI 10.1038/s43018-022-00337-6PMC PMC8882468

Open this paper in CoChat — free account

Abstract

Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug Administration (FDA)-approved drug with high efficacy against the models. Treatment with this therapy resulted in a complete response for the individual and a progression-free survival (PFS) period more than three times longer than their previous therapies. This work provides valuable methods and resources for functional precision medicine and drug development for human breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s43018-022-00337-6

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Self-citation
Integrative genomics viewer
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,037
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099

Show all 69 references

Research works printed but not linked: 2

Bruna, A. et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167, 260–274 (2016). · DOI
Carlson J. A., Garg R., Compton S. R., Zeiss C., & Uchio E. Poliomyelitis in SCID mice following injection of basement membrane matrix contaminated with lactate dehydrogenase-elevating virus. In Proc. 59th AALAS National Meeting 9–13 (AALAS, 2008).

Sorted by citations

Organoids
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 533
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 354
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations
Letai, A. G., Bhola, P. D., & Welm, A. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 282
Self-citation
Organoids: The current status and biomedical applications
Yang, S., Hu, H., Kung, H., Zou, R.-Q., Dai, Y.-S., Hu, Y.-F., Wang, T., Lv, T., Yu, J., & Li, F. (2023) · MedComm · doi:10.1002/mco2.274 · Cited by 300
Recent advances and clinical translation of liposomal delivery systems in cancer therapy
Chen, J., Hu, S., Sun, M., Shi, J., Zhang, H., Yu, H., & Yang, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106688 · Cited by 233
Drug screening at single-organoid resolution via bioprinting and interferometry
Tebon, P. J., Wang, B., Markowitz, A. L., Davarifar, A., Tsai, B. L., Krawczuk, P., Gonzalez, A. E., Sartini, S., Murray, G. F., Nguyen, H. T. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38832-8 · Cited by 163
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 154
Acquired resistance in cancer: towards targeted therapeutic strategies
Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
Transferred mitochondria accumulate reactive oxygen species, promoting proliferation
Kidwell, C. U., Casalini, J. R., Pradeep, S., Scherer, S. D., Greiner, D., Bayık, D., Watson, D. C., Olson, G. S., Lathia, J. D., Johnson, J. S., et al. (2023) · eLife · doi:10.7554/elife.85494 · Cited by 112
Self-citation
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Salemme, V., Centonze, G., Avalle, L., Natalini, D., Piccolantonio, A., Arina, P., Morellato, A., Ala, U., Taverna, D., Turco, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170264 · Cited by 106
Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics
Bhatia, S., Kramer, M., Russo, S., Naik, P., Arun, G., Brophy, K., Andrews, P., Fan, C., Perou, C. M., Preall, J. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2807 · Cited by 103
Data analysis guidelines for single-cell RNA-seq in biomedical studies and clinical applications
Su, M., Pan, T., Chen, Q.-Z., Zhou, W., Gong, Y., Xu, G., Yan, H.-Y., Li, S., Shi, Q.-Z., Zhang, Y., et al. (2022) · Military Medical Research · doi:10.1186/s40779-022-00434-8 · Cited by 114
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine
Yao, Q., Cheng, S., Pan, Q., Yu, J., Cao, G., Li, L., & Cao, H. (2024) · MedComm · doi:10.1002/mco2.735 · Cited by 100
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment
Tosca, E. M., Ronchi, D., Facciolo, D., & Magni, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041058 · Cited by 95
Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
Derouane, F., van Marcke, C., Berlière, M., Gerday, A., Fellah, L., Leconte, I., Bockstal, M. V., Galant, C., Corbet, C., & Duhoux, F. P. (2022) · Cancers · doi:10.3390/cancers14163876 · Cited by 93
Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 101
Complex in vitro model: A transformative model in drug development and precision medicine
Wang, L., Hu, D., Xu, J., Hu, J., & Wang, Y. (2023) · Clinical and Translational Science · doi:10.1111/cts.13695 · Cited by 87
Untangling the web of intratumour heterogeneity
Li, Z., Seehawer, M., & Polyák, K. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00969-x · Cited by 82
Self-citation
Role of Patient-Derived Models of Cancer in Translational Oncology
Idrisova, K., Simon, H., & Gomzikova, M. O. (2022) · Cancers · doi:10.3390/cancers15010139 · Cited by 84
Patient‐derived xenograft model in cancer: establishment and applications
Gu, A., Li, J., Li, M., & Liu, Y. (2025) · MedComm · doi:10.1002/mco2.70059 · Cited by 82
The landscape of drug sensitivity and resistance in sarcoma
Shihabi, A. A., Tebon, P. J., Nguyen, H. T. L., Chantharasamee, J., Sartini, S., Davarifar, A., Jensen, A. Y., Diaz-Infante, M. B., Cox, H., Gonzalez, A. E., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.08.010 · Cited by 79
GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids
Bock, N., Forouz, F., Hipwood, L., Clegg, J., Jeffery, P. L., Gough, M., van Wyngaard, T., Pyke, C., Adams, M. N., Bray, L. J., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010261 · Cited by 73
Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies
Zhou, Z., Pang, Y., Ji, J., He, J., Liu, T., Ouyang, L., Zhang, W., Zhang, X., Zhang, Z., Zhang, K., et al. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00896-4 · Cited by 79
From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research
Rauner, G., Gupta, P. B., & Kuperwasser, C. (2025) · Nature Methods · doi:10.1038/s41592-025-02769-1 · Cited by 82
Trellis tree-based analysis reveals stromal regulation of patient-derived organoid drug responses
Ramos Zapatero, M., Tong, A., Opzoomer, J. W., O’Sullivan, R., Cardoso Rodriguez, F., Sufi, J., Vlckova, P., Nattress, C., Qin, X., Claus, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.11.005 · Cited by 72
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Schade, A. E., Perurena, N., Yang, Y., Rodriguez, C. L., Krishnan, A., Gardner, A., Loi, P., Xu, Y., Nguyen, V. T. M., Mastellone, G. M., et al. (2024) · Nature · doi:10.1038/s41586-024-08031-6 · Cited by 72
Self-citation
Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models
Wang, E., Xiang, K., Zhang, Y., & Wang, X.-F. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.001 · Cited by 56
EMT and cancer: what clinicians should know
Thompson, E. W., Redfern, A. D., Brabletz, S., Berx, G., Agarwal, V., Ganesh, K., Huang, R. Y., Ishay-Ronen, D., Savagner, P., Sheng, G., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01058-2 · Cited by 71
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Tufail, M., Hu, J.-J., Liang, J., He, C., Wan, W., Huang, Y., Jiang, C., Wu, H., & Li, N. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04841-w · Cited by 65
Patient‐derived xenograft models in pan‐cancer: From bench to clinic
Li, J., Gu, A., Tang, N., Zengin, G., Li, M., & Liu, Y. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20250016 · Cited by 62
The role of organoids in cancer research
Fang, Z., Li, P., Du, F., Shang, L., & Li, L. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00433-y · Cited by 68
3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 63
Exploring the interaction between extracellular matrix components in a 3D organoid disease model to replicate the pathophysiology of breast cancer
Bhattacharya, A., Alam, K., Roy, N. S., Kaur, K., Kaity, S., Ravichandiran, V., & Roy, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02926-4 · Cited by 62
Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer
Polanco, E. R., Moustafa, T. E., Butterfield, A., Scherer, S. D., Cortes-Sanchez, E., Bodily, T. A., Spike, B. T., Welm, B. E., Bernard, P. S., & Zangle, T. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03759-1 · Cited by 56
Self-citation
Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
Sflomos, G., Schipper, K., Koorman, T., Fitzpatrick, A., Oesterreich, S., Lee, A. V., Jonkers, J., Brunton, V. G., Christgen, M., Isacke, C. M., et al. (2021) · Cancers · doi:10.3390/cancers13215396 · Cited by 51
Self-citation
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial
Wu, S., Jin, X., Liu, Y., Wang, Z.-Y., Zuo, W., Ma, D., Xiao, Y., Fu, T., Xiao, Y.-L., Chen, L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03776-7 · Cited by 51
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Lin, C.-C. A., Chang, T.-C., Wang, Y., Guo, L., Gao, Y., Bikorimana, E., Lemoff, A. S., Fang, Y. V., Zhang, H., Zhang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46495-2 · Cited by 53
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions
Wang, S., Wu, W., Lin, X., Zhang, K. M., Wu, Q., Luo, M., & Zhou, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01171-8 · Cited by 47
An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
Scherer, S. D., Riggio, A. I., Haroun, F., DeRose, Y. S., Ekiz, H. A., Fujita, M., Toner, J., Zhao, L., Li, Z., Oesterreich, S., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01476-x · Cited by 44
Self-citation
Advancing cancer research through organoid technology
Zeng, G., Yu, Y., Wang, M., Liu, J., He, G., Yu, S., Yan, H., Yang, L., Li, H., & Peng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05824-1 · Cited by 43
FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer
Casalino, L., Talotta, F., Matino, I., & Verde, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098307 · Cited by 45
Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice
Chen, A., Neuwirth, I., & Herndler‐Brandstetter, D. (2023) · Cancers · doi:10.3390/cancers15112989 · Cited by 44
Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research
Ferreira, T., Gama, A., Seixas, F., Faustino‐Rocha, A. I., Lopes, C., Gaspar, V. M., Mano, J. F., Medeiros, R., & Oliveira, P. A. (2023) · Veterinary Sciences · doi:10.3390/vetsci10060379 · Cited by 45
Organoids: opportunities and challenges of cancer therapy
Jiang, X., Oyang, L., Qiu, P., Liu, Q., Xu, X., Wu, N., Tan, S., Yang, W., Han, Y., Lin, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232528 · Cited by 41
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
Liu, M., & Yang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101520 · Cited by 44
OBSERVE: guidelines for the refinement of rodent cancer models
Vleeschauwer, S. I. D., van de Ven, M., Oudin, A., Debusschere, K., Connor, K., Byrne, A. T., Ram, D., Rhebergen, A. M., Raeves, Y. D., Dahlhoff, M., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00998-w · Cited by 40
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer
Truong, T. H., Benner, E., Hagen, K. M., Temiz, N. A., Kerkvliet, C. J. P., Wang, Y., Cortes-Sanchez, E., Yang, C.-H., Trousdell, M. C., Pengo, T., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01871-w · Cited by 39
Self-citation
In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
Souto, E. P., Dobrolecki, L. E., Villanueva, H. J., Sikora, A. G., & Lewis, M. T. (2022) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-022-09520-y · Cited by 38
Self-citation
Functional Drug Screening in the Era of Precision Medicine
Napoli, G. C., Figg, W. D., & Chau, C. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.912641 · Cited by 41
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 38
Self-citation
Organoid‐Guided Precision Medicine: From Bench to Bedside
Tao, B., Li, X., Hao, M., Tian, T., Li, Y., Li, X., Yang, C., Li, Q., Feng, Q., Zhou, H., et al. (2025) · MedComm · doi:10.1002/mco2.70195 · Cited by 38
Self-citation
O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer
Zhang, Y., Zhou, S., Kai, Y., Zhang, Y.-Q., Peng, C., Li, Z., Jameel, M., Belmar, J., Zheng, X., Ma, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49875-w · Cited by 37
Self-citation
Circulating tumor cell-derived preclinical models: current status and future perspectives
Kahounová, Z., Pícková, M., Drápela, S., Bouchal, J., Szczyrbová, E., Navrátil, J., & Souček, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06059-6 · Cited by 37
Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
Fisher, N. C., Byrne, R. M., Leslie, H., Wood, C. S., Legrini, A., Cameron, A. J., Ahmaderaghi, B., Corry, S. M., Malla, S. B., Amirkhah, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1102 · Cited by 36
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Hynds, R. E., Huebner, A., Pearce, D. R., Hill, M. S., Akarca, A. U., Moore, D. A., Ward, S., Gowers, K. H. C., Karasaki, T., Bakir, M. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47547-3 · Cited by 36
Self-citation
A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses
Raffo‐Romero, A., Ziane-Chaouche, L., Salomé‐Desnoulez, S., Hajjaji, N., Fournier, I., Salzet, M., & Duhamel, M. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100792 · Cited by 36
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
Petrosyan, V., Dobrolecki, L. E., Thistlethwaite, L. R., Lewis, A. N., Sallas, C., Srinivasan, R. R., Lei, J. T., Kovačević, V., Obradović, P., Ellis, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105799 · Cited by 38
Self-citation
Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Stutheit-Zhao, E. Y., Sanz‐García, E., Liu, Z. A., Wong, D., Marsh, K., Razak, A. R. A., Spreafico, A., Bedard, P. L., Hansen, A. R., Lheureux, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1060 · Cited by 35
Characterisation of cell lines derived from prostate cancer patients with localised disease
Moya, L., Walpole, C., Rae, F., Srinivasan, S., Seim, I., Lai, J., Nicol, D. L., Williams, E. D., Clements, J. A., & Batra, J. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00679-x · Cited by 38
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 34
Recent advances in breast cancer cell line research
Sharma, M. P., Shukla, S., & Misra, G. (2024) · International Journal of Cancer · doi:10.1002/ijc.34849 · Cited by 33
Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers
Derouane, F., Desgres, M., Moroni, C., Ambroise, J., Berlière, M., Bockstal, M. V., Galant, C., van Marcke, C., Vara-Messler, M., Hutten, S. J., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01788-8 · Cited by 34
Stem Cells and Organoids: A Paradigm Shift in Preclinical Models Toward Personalized Medicine
Luce, E., & Duclos‐Vallée, J. (2025) · Pharmaceuticals · doi:10.3390/ph18070992 · Cited by 34
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Zhang, S., Shen, J., Wang, X., Sun, X., Wu, Y., Zhang, M., Wang, R., & Hu, K. (2023) · Open Research (University of Surrey) · doi:10.1002/viw.20230010 · Cited by 33
Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients
Khorsandi, D., Yang, J., Foster, S., Khosravi, S., Kouchehbaghi, N. H., Zarei, F., Lee, Y. B., Runa, F., Gangrade, A., Voskanian, L., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302331 · Cited by 33
The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research
Bittman-Soto, X. S., Thomas, E. S., Ganshert, M., Mendez‐Santacruz, L. L., & Harrell, J. C. (2024) · Cancers · doi:10.3390/cancers16101859 · Cited by 31
Three-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research
Azimian, V., Rafiee, L., Sheikholeslam, M., Shariati, L., Vaseghi, G., Savoji, H., & Javanmard, S. H. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00277 · Cited by 31
Precision oncology: current and future platforms for treatment selection
Tang, X., Berger, M. F., & Solit, D. B. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.009 · Cited by 32
Cancer brain metastasis: molecular mechanisms and therapeutic strategies
Lu, Y., Huang, Y., Zhu, C., Li, Z., Zhang, B., Sheng, H., Li, H., Liu, X., Xu, Z., Wen, Y., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00251-0 · Cited by 29
Self-citation
Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish
Singhal, S. S., Garg, R., Mohanty, A. R., Garg, P., Ramisetty, S. K., Mirzapoiazova, T., Soldi, R., Sharma, S., Kulkarni, P., & Salgia, R. (2023) · Cancers · doi:10.3390/cancers15112961 · Cited by 32
Simultaneous isolation of hormone receptor–positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms
Högström, J., Cruz, K. A., Selfors, L. M., Ward, M. N., Mehta, T. S., Kanarek, N., Philips, J., Dialani, V. M., Wulf, G. M., Collins, L. C., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105021 · Cited by 28
Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening
Choi, S. Y., Shim, J., Gu, D., Kim, S. Y., Kim, H. J., Shin, D., & Chung, M. K. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106571 · Cited by 28
A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine
Kalla, J., Pfneissl, J., Mair, T., Tran, L., & Egger, G. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00960-8 · Cited by 31
The roles of patient‐derived xenograft models and artificial intelligence toward precision medicine
Babu, J. V., ArulJothi, K. N., Mythili, V. M. R., Singh, S. K., Prasher, P., Gupta, G., Dua, K., Rakshith, H. S., Kaliappan, K., & Anand, K. (2024) · MedComm · doi:10.1002/mco2.745 · Cited by 28
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma
Thorel, L., Morice, P., Paysant, H., Florent, R., Babin, G., Thomine, C., Perréard, M., Abeilard, E., Giffard, F., Brotin, É., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02809-8 · Cited by 28
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 28
Patient-derived organoids: a promising tool for breast cancer research
Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350935 · Cited by 29
Rat Models of Hormone Receptor-Positive Breast Cancer
Nicotra, R., Lutz, C., Messal, H. A., & Jonkers, J. (2024) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-024-09566-0 · Cited by 30
A review of 3D bioprinting for organoids
Li, Z., Chen, L., Wu, J., Chen, Y., Zhu, Y. Z., Li, G., Xie, G., Tang, G., & Xie, M. (2025) · Medical Review · doi:10.1515/mr-2024-0089 · Cited by 27
Self-citation
Estrogen regulates divergent transcriptional and epigenetic cell states in breast cancer
Ors, A., Chitsazan, A., Doe, A. R., Mulqueen, R. M., Ak, Ç., Wen, Y., Haverlack, S., Handu, M., Naldiga, S., Saldivar, J. C., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac908 · Cited by 26
Selective inhibition of CDK9 in triple negative breast cancer
Mustafa, E. H., Laven‐Law, G., Kikhtyak, Z., Nguyen, V. T. M., Ali, S., Pace, A. A., Iggo, R. D., Kebede, A., Noll, B., Wang, S., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02892-3 · Cited by 27
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu, Y., Lankadasari, M. B., Rosiene, J. A., Johnson, K. E., Zhou, J., Bapat, S., Chow-Tsang, L.-F., Tian, H., Mastrogiacomo, B., He, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101777 · Cited by 25
Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
Abbasian, M. H., Sobhani, N., Sisakht, M. M., D’Angelo, A., Sirico, M., & Roudi, R. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10805-4 · Cited by 28
Cryo‐Shocked Tumor‐Reprogrammed Sonosensitive Antigen‐Presenting Cells Improving Sonoimmunotherapy via T Cells and NK Cells Immunity
Qian, X., Yi, W., Yan, W., Cai, Y., Hu, S., Yan, D., Zhao, Z., Li, R. H., Wang, L., Xu, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202413289 · Cited by 26
A combined enteric neuron-gastric tumor organoid reveals metabolic vulnerabilities in gastric cancer
Chan, B. K. C., Zhang, C., Poon, C. H., Lee, M. H. Y., Chu, H. Y., Wang, B., Chen, S.-G., Yan, H. H. N., Leung, S. Y., & Wong, A. S. L. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.08.006 · Cited by 25
Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity
Preković, S., Chalkiadakis, T., Roest, M., Roden, D. L., Lutz, C., Schuurman, K. G., Opdam, M., Hoekman, L., Abbott, N., Tesselaar, T., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317737 · Cited by 26
Preclinical Models of Brain Metastases in Breast Cancer
Knier, N. N., Pellizzari, S., Zhou, J., Foster, P. J., & Parsyan, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10030667 · Cited by 22
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer
Echeverria, G. V., Cai, S., Tu, Y., Shao, J., Powell, E., Redwood, A. B., Jiang, Y., McCoy, A., Rinkenbaugh, A. L., Lau, R., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00502-1 · Cited by 22
In vitro co-culture models for studying organoids-macrophages interaction: the golden technology of cancer immunotherapy
Liu, J. (2024) · American Journal of Cancer Research · doi:10.62347/bqfh7352 · Cited by 21
Targeting alternative splicing in cancer immunotherapy
Han, N., & Liu, Z. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232146 · Cited by 21
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”
Lim, B., Seth, S., Yam, C., Huo, L., Fujii, T., Lee, J., Bassett, R. L., Nasser, S., Ravenberg, L., White, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101595 · Cited by 22
Self-citation
3D Tumor Models for Breast Cancer: Whither We Are and What We Need
Balachander, G. M., Kotcherlakota, R., Nayak, B., Kedaria, D., Rangarajan, A., & Chatterjee, K. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00230 · Cited by 21
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers
Soosainathan, A., Iravani, M., Botty, R. E., Alexander, J. J., Sourd, L., Morisset, L., Painsec, P., Orha, R., Nikitorowicz-Buniak, J., Pancholi, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0650 · Cited by 20
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method
Feng, Q.-S., Shan, X., Yau, V., Cai, Z., & Xie, S. (2025) · Pharmaceuticals · doi:10.3390/ph18010062 · Cited by 21
Rational design matrix materials for organoid development and application in biomedicine
Huang, Y. F., Zhang, X., Zhang, W., Tang, J., & Liu, J. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf038 · Cited by 22
Clinical applications of 3D normal and breast cancer organoids: A review of concepts and methods
Lewis, S. M., Callaway, M. K., & dos Santos, C. O. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221131877 · Cited by 20

Authors: Guillen, K. P., Fujita, M., Butterfield, A. J., Scherer, S. D., Bailey, M. H., Chu, Z., DeRose, Y. S., Zhao, L., Cortes-Sanchez, E., Yang, C.-H., Toner, J., Wang, G., Qiao, Y., Huang, X., Greenland, J. A., Vahrenkamp, J. M., Lum, D. H., Factor, R. E., Nelson, E. W., Matsen, C. B., Poretta, J. M., Rosenthal, R., Beck, A. C., Buys, S. S., Vaklavas, C., Ward, J. H., Jensen, R. L., Jones, K. B., Li, Z., Oesterreich, S., Dobrolecki, L. E., Pathi, S. S., Woo, X. Y., Berrett, K. C., Wadsworth, M. E., Chuang, J. H., Lewis, M. T., Marth, G. T., Gertz, J., Varley, K. E., Welm, B. E., & Welm, A. L.
Affiliations: University of Utah (US)
Huntsman Cancer Institute (US)
University of Pittsburgh (US)
Baylor College of Medicine (US)
The Jackson Laboratory for Genomic Medicine (US)
Corresponding author: Welm, Bryan E.
Welm, Alana L.
ORCID: Fujita, Maihi
Scherer, Sandra D.
Bailey, Matthew H.
Chu, Zhengtao
Zhao, Ling
Cortes-Sanchez, Emilio
Huang, Xiaomeng
Vahrenkamp, Jeffery M.
Lum, David H.
Factor, Rachel E.
Nelson, Edward W.
Matsen, Cindy B.
Beck, Anna C.
Buys, Saundra S.
Vaklavas, Christos
Ward, John H.
Jensen, Randy L.
Jones, Kevin B.
Li, Zheqi
Oesterreich, Steffi
Dobrolecki, Lacey E.
Woo, Xing Yi
Berrett, Kristofer C.
Wadsworth, Mark E.
Chuang, Jeffrey H.
Lewis, Michael T.
Gertz, Jason
Varley, Katherine E.
Welm, Bryan E.
Welm, Alana L.
Venue: Nature Cancer
Publisher: Springer Science and Business Media LLC
Published: 2022-02-24
Volume: 3
Issue: 2
Pages: 232-250
ISSN: 2662-1347 (ISSN-L)
DOI: 10.1038/s43018-022-00337-6
PMC: PMC8882468
OpenAlex: W4214507610
Cited by: 416
References: 69
Citations by year: 2026: 87 · 2025: 99 · 2024: 104 · 2023: 78 · 2022: 43
FWCI: 33.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Cancer (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Digital Commons-TMC (Texas Medical Center) (submittedVersion)
The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders: U.S. Department of Defense (W81XWH1210077, W81XWH1410417)
American Cancer Society (P30 CA042014)
Breast Cancer Research Foundation
Cancer Prevention and Research Institute of Texas (CA125123, RP170691)
University of Utah (P30 CA042014)
Huntsman Cancer Foundation (P30CA042014)
Huntsman Cancer Institute (P30CA042014)
National Institutes of Health (/ NCI R01, CA125123)
National Human Genome Research Institute (T32HG008962)
National Cancer Institute (R01CA221303, NCI-CA125123, CA125123, U01CA217617, U54CA224076, U24CA224067, P30CA042014, P30CA125123)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
Keywords: breast cancer, patient-derived xenografts, organoids, endocrine-resistant breast cancer, metastatic breast cancer, triple-negative breast cancer, precision oncology, drug screening, drug repurposing, treatment-refractory cancer
MeSH terms: Humans, Organoids, United States, Xenograft Model Antitumor Assays, Drug Discovery, Precision Medicine, Heterografts, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks